 BOSTON--BUSINESS WIRE--AVEO Oncology Nasdaq: AVEO today reported financial results for the full year ended December 31, 2020 and provided a business update. The U.S. Food and Drug Administrations FDA recent approval of FOTIVDA marks a transformative event for AVEO, and we are eager to demonstrate FOTIVDAs potential to serve as a meaningful new treatment option within the growing relapsed or refractory advanced renal cell carcinoma RCC patient population. We look forward to bringing t 